Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
138.50
+1.00 (0.73%)
Oct 22, 2025, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Revenue
Jazz Pharmaceuticals had revenue of $1.05B in the quarter ending June 30, 2025, with 2.14% growth. This brings the company's revenue in the last twelve months to $4.09B, up 4.52% year-over-year. In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth.
Revenue (ttm)
$4.09B
Revenue Growth
+4.52%
P/S Ratio
2.05
Revenue / Employee
$1,459,534
Employees
2,800
Market Cap
8.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
JAZZ News
- 1 day ago - Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer - Business Wire
- 5 days ago - 3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street - Benzinga
- 19 days ago - FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - PRNewsWire
- 20 days ago - US FDA approves Jazz Pharma's therapy for lung cancer - Reuters
- 4 weeks ago - Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating - Seeking Alpha
- 4 weeks ago - Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses - PRNewsWire
- 6 weeks ago - Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha